|Articles|May 1, 2007
- Pharmaceutical Executive-05-01-2007
- Volume 0
- Issue 0
The Pharm Exec 50: Holding Pattern
The top 50 pharmaceutical companies, ranked by prescription pharmaceutical drug sales, plus rankings of top products, R&D spend, and more.
Advertisement
Articles in this issue
about 19 years ago
Kid Tested, Government Approved?about 19 years ago
Leadership: Getting on Boardabout 19 years ago
Spend Trends 2007: Hang 10about 19 years ago
The Secretabout 19 years ago
Marketing to Professionals: No Sales Force, No Problemabout 19 years ago
Opinion: Are Price Controls the New Black?about 19 years ago
Toolkit: How To Be a Better Partnerabout 19 years ago
Washington Report: Pathways for Proteinsabout 19 years ago
Global Report: Pure and Simpleabout 19 years ago
Thoughtleader: Thomas Nagle, Monitor GroupAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
2
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
3
The Evolving Relationship Between FDA and Biotech
4
Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand Strategic Collaboration
5